Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models

Figure 2

In vivo antitumor activity of ET-743 in human BTC preclinical models. The graphs indicate the mean tumor volume (cm3) weekly measured: 0 (start of treatment), 7, 14, and 21 days after treatment with ET-743 (weekly 0.15 mg/Kg ET-743 or PBS in mice control cohort) (error bars: SEM). Seven mice for each arm of treatment in three independent experiments were used. One week after the last drug administration, a significant slow of tumor growth was shown in treated mice in both CHC001PDX (A) and EGI-1-xenografts (B). Ki67 staining of section derived from CHC001PDX (C) and EGI-1 xenograft (D) tumors treated with PBS or ET-743 and relative quantification. A statistical significant reduction of Ki67 positive cells was revealed in the ET-743-treated CHC001PDX group.

Back to article page